European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma
March 13, 2026 – Oncopeptides today announces the publication of a new real-world study in the peer-reviewed European Journal of Haematology. The study, conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, confirms the efficacy and safety of Pepaxti (melflufen) plus dexamethasone. The heavily pretreated patients, including those refractory to novel immunotherapies, benefitted from Pepaxti’s strong efficacy, the overall response rate (ORR) was 41% with a median progression-free survival (mPFS) of 9.0 months.
Read more and Q&A for investors

CEO Sofia Heigis presents Oncopeptides at Aktiespararna
March 11, 2026 – Oncopeptides CEO Sofia Heigis recently presented the company at an Aktiespararna event in Stockholm.
Watch the presentation